Literature DB >> 26829210

Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.

Aina Teniente-Serra1,2, Laia Grau-López3, M José Mansilla1,2, Marco Fernández-Sanmartín4, Anna Ester Condins5, Cristina Ramo-Tello3, Eva Martínez-Cáceres1,2.   

Abstract

OBJECTIVE: The objective of this study is to characterise the functionally relevant minor lymphocyte subpopulations in whole blood of multiple sclerosis (MS) patients and their potential utility as biomarkers for treatment follow up.
MATERIAL AND METHODS: Peripheral blood from 40 healthy donors (HD) and 66 MS patients [23 relapsing-remitting (RRMS) without treatment, 27 RRMS undergoing treatment (16 IFN-β, 11 natalizumab), and 16 progressive forms (eight secondary progressive and eight primary progressive)] was analysed by multiparametric flow cytometry.
RESULTS: Untreated MS patients showed a decrease in early effector memory (CD45RA(-)CCR7(-)CD27(+)) CD4(+) and CD8(+) T cells and an increase in Th17 lymphocytes in peripheral blood compared with HD. Regarding the effect of treatment, whereas no differences in relative percentages of cellular subpopulations were observed in patients under IFN-β treatment, those under treatment with natalizumab had an increased percentage of early effector memory CD4(+) (CD45RA(-)CCR7(-)CD27(+)), central memory CD8(+) (CD45RA(-)CCR7(+)CD27(+)) T cells, recent thymic emigrants (CD4(+) CD45RA(+)CCR7(+)CD27(+)CD31(+)PTK7(+)) and transitional B cells (CD19(+)CD27(-)CD24(hi)CD38(hi)).
CONCLUSIONS: Multiparametric flow cytometry analysis of whole blood is a robust, reproducible, and sensitive technology to monitor the effect of MS treatments even in minor lymphocyte subpopulations that might represent useful biomarkers of treatment response.

Entities:  

Keywords:  Immunomonitoring; interferon-β; lymphocyte subpopulations; multiple sclerosis; natalizumab

Mesh:

Substances:

Year:  2016        PMID: 26829210     DOI: 10.3109/08916934.2016.1138271

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  9 in total

1.  Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.

Authors:  Bibiana Quirant-Sánchez; José V Hervás-García; Aina Teniente-Serra; Luis Brieva; Ester Moral-Torres; Antonio Cano; Elvira Munteis; María J Mansilla; Silvia Presas-Rodriguez; Juan Navarro-Barriuso; Cristina Ramo-Tello; Eva M Martínez-Cáceres
Journal:  CNS Neurosci Ther       Date:  2018-04-15       Impact factor: 5.243

Review 2.  Circulating immune cells in multiple sclerosis.

Authors:  A P Jones; A G Kermode; R M Lucas; W M Carroll; D Nolan; P H Hart
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

Review 3.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

4.  Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis.

Authors:  João Canto-Gomes; Carolina S Silva; Rita Rb-Silva; Daniela Boleixa; Ana Martins da Silva; Rémi Cheynier; Patrício Costa; Inés González-Suárez; Margarida Correia-Neves; João J Cerqueira; Claudia Nobrega
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

5.  T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.

Authors:  Sonja Dulic; Zsófia Vásárhelyi; Florentina Sava; László Berta; Balázs Szalay; Gergely Toldi; László Kovács; Attila Balog
Journal:  Mediators Inflamm       Date:  2017-10-25       Impact factor: 4.711

Review 6.  Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.

Authors:  David Baker; Monica Marta; Gareth Pryce; Gavin Giovannoni; Klaus Schmierer
Journal:  EBioMedicine       Date:  2017-01-31       Impact factor: 8.143

7.  Lymphocyte reconstitution following autologous stem cell transplantation for progressive MS.

Authors:  G Cull; D Hall; M J Fabis-Pedrini; W M Carroll; L Forster; F Robins; R Ghassemifar; C Crosbie; S Walters; I James; B Augustson; A K Kermode
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-03-23

8.  Impact of treatment on cellular immunophenotype in MS: A cross-sectional study.

Authors:  Maria Cellerino; Federico Ivaldi; Matteo Pardini; Gianluca Rotta; Gemma Vila; Priscilla Bäcker-Koduah; Tone Berge; Alice Laroni; Caterina Lapucci; Giovanni Novi; Giacomo Boffa; Elvira Sbragia; Serena Palmeri; Susanna Asseyer; Einar Høgestøl; Cristina Campi; Michele Piana; Matilde Inglese; Friedemann Paul; Hanne F Harbo; Pablo Villoslada; Nicole Kerlero de Rosbo; Antonio Uccelli
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-05

9.  Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.

Authors:  Emanuele D'Amico; Aurora Zanghì; Nunziatina Laura Parrinello; Alessandra Romano; Giuseppe Alberto Palumbo; Clara Grazia Chisari; Simona Toscano; Francesco Di Raimondo; Mario Zappia; Francesco Patti
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.